Company regains compliance with Nasdaq’s minimum bid price requirement and intends to request a Nasdaq Hearings Panel hearing to seek additional time to regain compliance with the minimum market value requirement CAMBRIDGE, Mass., Oct. 2, 2026 /PRNewswire/ — NeuroSense Therapeutics Ltd….
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
